Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab
To the best of our knowledge, this is the first documentation demonstrating that atezolizumab is transported to CD63-positive organelles, thereby enhancing our understanding of its intracellular trafficking. Our study also strengthens the concept of PIT and atezolizumab-based targeting of PD-L1<sup>+</sup> NSCLCs.
Authors
- Simone Civita (ORCID: https://orcid.org/0000-0001-9059-6933)
- Ellen Skarpen
- Matteo Mariangeli (ORCID: https://orcid.org/0000-0001-8069-6164)
- Alberto Diaspro (ORCID: https://orcid.org/0000-0002-4916-5928)
- Pål Kristian Selbo (ORCID: https://orcid.org/0000-0002-5310-057X)
- Stefania Abbruzzetti (ORCID: https://orcid.org/0000-0001-7685-8554)
- Anette Weyergang (ORCID: https://orcid.org/0000-0003-0147-1763)
- Magdaléna Kozlíková (ORCID: https://orcid.org/0000-0001-8742-1163)
- Paolo Bianchini (ORCID: https://orcid.org/0000-0001-6457-751X)
- Pietro Delcanale (ORCID: https://orcid.org/0000-0001-8235-765X)
- Kristian Berg (ORCID: https://orcid.org/0000-0002-7816-7543)
- Andrea Mussini (ORCID: https://orcid.org/0000-0001-5363-7150)
- Cristiano Viappiani (ORCID: https://orcid.org/0000-0001-7470-4770)
- Manuela Maria Alampi (ORCID: https://orcid.org/0000-0003-1996-4507)
Institutions
- University of Parma (IT)
- Oslo University Hospital (NO)
- Charles University (CZ)
- Norwegian Cancer Society (NO)
- Italian Institute of Technology (IT)
- University Hospital Hradec Králové (CZ)
- University of Hradec Králové (CZ)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1016/j.biopha.2025.118550
- Citations
- 1
- Primary Topic
- Photodynamic Therapy Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.52